Publications by authors named "S Skoda-Smith"

SAMD9L is an interferon-induced tumor suppressor implicated in a spectrum of multisystem disorders, including risk for myeloid malignancies and immune deficiency. We identified a heterozygous de novo frameshift variant in SAMD9L in an infant with B cell aplasia and clinical autoinflammatory features who died from respiratory failure with chronic rhinovirus infection. Autopsy demonstrated absent bone marrow and peripheral B cells as well as selective loss of Langerhans and Purkinje cells.

View Article and Find Full Text PDF

Genetic testing has increased the number of variants identified in disease genes, but the diagnostic utility is limited by lack of understanding variant function. CARD11 encodes an adaptor protein that expresses dominant-negative and gain-of-function variants associated with distinct immunodeficiencies. Here, we used a "cloning-free" saturation genome editing approach in a diploid cell line to simultaneously score 2,542 variants for decreased or increased function in the region of CARD11 associated with immunodeficiency.

View Article and Find Full Text PDF

The original version of this article unfortunately contained the missing author, Caridad Martinez. The authors would like to correct the list. We apologize for any inconvenience that this may have caused.

View Article and Find Full Text PDF
Article Synopsis
  • Allogeneic hematopoietic cell transplant (HCT) is a crucial treatment for patients with nonmalignant diseases but often limited by the lack of HLA-matched donors.
  • Recent studies on nonmyeloablative T cell-replete HLA-haploidentical transplants show promising outcomes in hematologic malignancies, encouraging further research in nonmalignant cases.
  • In a study of 23 patients, there was a 0% transplant-related mortality at day 100, and 2-year overall survival rates reached 91%, though strategies to reduce graft-versus-host disease (GVHD) are still needed to enhance treatment efficacy.
View Article and Find Full Text PDF

Primary Immune Regulatory Disorders (PIRD) are an expanding group of diseases caused by gene defects in several different immune pathways, such as regulatory T cell function. Patients with PIRD develop clinical manifestations associated with diminished and exaggerated immune responses. Management of these patients is complicated; oftentimes immunosuppressive therapies are insufficient, and patients may require hematopoietic cell transplant (HCT) for treatment.

View Article and Find Full Text PDF